Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Abstract Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical act...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0693-2 |
id |
doaj-872a7a94cba2431aa8871a735b9925ba |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bixia Tang Xieqiao Yan Xinan Sheng Lu Si Chuanliang Cui Yan Kong Lili Mao Bin Lian Xue Bai Xuan Wang Siming Li Li Zhou Jiayi Yu Jie Dai Kai Wang Jinwei Hu Lihou Dong Haifeng Song Hai Wu Hui Feng Sheng Yao Zhihong Chi Jun Guo |
spellingShingle |
Bixia Tang Xieqiao Yan Xinan Sheng Lu Si Chuanliang Cui Yan Kong Lili Mao Bin Lian Xue Bai Xuan Wang Siming Li Li Zhou Jiayi Yu Jie Dai Kai Wang Jinwei Hu Lihou Dong Haifeng Song Hai Wu Hui Feng Sheng Yao Zhihong Chi Jun Guo Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients Journal of Hematology & Oncology PD-1 Monoclonal antibody JS001 Melanoma Urothelial cancer Renal cell carcinoma |
author_facet |
Bixia Tang Xieqiao Yan Xinan Sheng Lu Si Chuanliang Cui Yan Kong Lili Mao Bin Lian Xue Bai Xuan Wang Siming Li Li Zhou Jiayi Yu Jie Dai Kai Wang Jinwei Hu Lihou Dong Haifeng Song Hai Wu Hui Feng Sheng Yao Zhihong Chi Jun Guo |
author_sort |
Bixia Tang |
title |
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients |
title_short |
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients |
title_full |
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients |
title_fullStr |
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients |
title_full_unstemmed |
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients |
title_sort |
safety and clinical activity with an anti-pd-1 antibody js001 in advanced melanoma or urologic cancer patients |
publisher |
BMC |
series |
Journal of Hematology & Oncology |
issn |
1756-8722 |
publishDate |
2019-01-01 |
description |
Abstract Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy. Patients and methods In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria. Results Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3− CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB). Conclusion JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology. Trial registration Clinical Trial ID: NCT02836795, registered July 19, 2016, retrospectively registered. |
topic |
PD-1 Monoclonal antibody JS001 Melanoma Urothelial cancer Renal cell carcinoma |
url |
http://link.springer.com/article/10.1186/s13045-018-0693-2 |
work_keys_str_mv |
AT bixiatang safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT xieqiaoyan safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT xinansheng safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT lusi safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT chuanliangcui safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT yankong safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT lilimao safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT binlian safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT xuebai safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT xuanwang safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT simingli safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT lizhou safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT jiayiyu safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT jiedai safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT kaiwang safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT jinweihu safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT lihoudong safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT haifengsong safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT haiwu safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT huifeng safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT shengyao safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT zhihongchi safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients AT junguo safetyandclinicalactivitywithanantipd1antibodyjs001inadvancedmelanomaorurologiccancerpatients |
_version_ |
1724939147875975168 |
spelling |
doaj-872a7a94cba2431aa8871a735b9925ba2020-11-25T02:05:16ZengBMCJournal of Hematology & Oncology1756-87222019-01-0112111510.1186/s13045-018-0693-2Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsBixia Tang0Xieqiao Yan1Xinan Sheng2Lu Si3Chuanliang Cui4Yan Kong5Lili Mao6Bin Lian7Xue Bai8Xuan Wang9Siming Li10Li Zhou11Jiayi Yu12Jie Dai13Kai Wang14Jinwei Hu15Lihou Dong16Haifeng Song17Hai Wu18Hui Feng19Sheng Yao20Zhihong Chi21Jun Guo22Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineOrigiMedOrigiMedDepartment of Pharmacology and Toxicology, Beijing Institute of Radiation MedicineDepartment of Pharmacology and Toxicology, Beijing Institute of Radiation MedicineShanghai Junshi Biosciences Co., Ltd.Shanghai Junshi Biosciences Co., Ltd.Shanghai Junshi Biosciences Co., Ltd.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer MedicineAbstract Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical activity of JS001 in advanced melanoma or urologic cancer patients who are refractory to standard systemic therapy. Patients and methods In the dose escalation cohorts, subjects initially received a single-dose, intravenous infusion of JS001, and were followed for 28 days followed by multi-dose infusions every 2 weeks. In the dose expansion cohorts, subjects received multi-dose infusions every 2 weeks. Clinical response was evaluated after each 8-week treatment cycle according to RECIST v1.1 criteria. Results Thirty-six subjects diagnosed with advanced melanoma (n = 22), urothelial cancer (UC) (n = 8), or renal cell cancer (RCC) (n = 6) were enrolled. Melanoma subjects included 14 acral and 4 mucosal subtypes. JS001 was well tolerated, and no dose-limiting toxicity was observed. By the safety data cutoff date, 100% of subjects had treatment-related adverse events (TRAE) with most adverse events being grade 1 or 2, and ≥ grade 3 TRAEs occurred in 36%. Among all 36 subjects, 1 confirmed complete response (acral melanoma), 7 confirmed partial responses (2 acral melanoma, 1 mucosal melanoma, 2 UC, and 2 RCC), and 10 stable disease were observed, for an objective response rate of 22.2% (95% CI, 10.1 to 39.2), and a disease control rate of 50.0% (95% CI, 32.9 to 67.1). Clinical responses were correlated with PD-L1 expression on tumor cells, the presence of tumor infiltrating lymphocytes (TIL), baseline tumor volume, ECOG performance status, serum LDH levels, high percentage of activated CD8+ T cells and CD3− CD16+ CD54+ NK cells in the peripheral blood as well as tumor mutational burden (TMB). Conclusion JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes. Subjects with an immune-active profile in the tumor microenvironment or in peripheral blood responded favorably to JS001 treatment. The completion of the current phase I study has led to the initiation of the first prospective anti-PD-1 registration trial in Asia focusing on acral and mucosal melanoma subtypes, representative of the regional disease epidemiology. Trial registration Clinical Trial ID: NCT02836795, registered July 19, 2016, retrospectively registered.http://link.springer.com/article/10.1186/s13045-018-0693-2PD-1Monoclonal antibodyJS001MelanomaUrothelial cancerRenal cell carcinoma |